Targeted therapies for the treatment of cancer

American Journal of Surgery

Volumn 186, Issue 3, 2003, Pages 264-268

  Kim, Julian A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

C kit; Cancer; Gleevec; HER 2 neu; Herceptin; Monoclonal antibodies; Rituxan; Targeted therapies

Indexed keywords

ABELSON KINASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CD20 ANTIGEN; CELL SURFACE RECEPTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; IMATINIB; INTERFERON; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRASTUZUMAB; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER THERAPY; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DNA REPAIR; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; REVIEW; SERUM SICKNESS; SIGNAL TRANSDUCTION; TUMOR GROWTH; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; MALE; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0141501192     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(03)00212-5     Document Type: Note

References (32)

1. Rydberg B. Radiation-induced DNA damage and chromatin structure. Acta Oncol. 40:2001;682-685.
2. Marchetti P., Urien S., Cappellini G.A., et al. Weekly administration of paclitaxel theoretical and clinical basis. Crit Rev Oncol Hematol. 44:(suppl):2002;3-13.
3. Moertel C.G. Accomplishments in surgical adjuvant therapy for large bowel cancer. Cancer. 70:(suppl):1992;1364-1371.
4. Harries M., Gore M. Part I chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3:2002;529-536.
5. Fisher B., Redmond C., Legault-Poisson S., et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 8:1990;1005-1018.
6. Kohler G., Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 6:1976;511-519.
7. Lanza F., Moretti S., Latorraca A., et al. Moving towards the definition of new clusters of designation at the 6th international workshop on human leukocyte differentiation antigens. A brief description of the recently clustered molecules. Eur J Histochem. 40:(suppl 1):1996;63-74.
8. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 91:1998;1644-1652.
9. Pedersen I.M., Buhl A.M., Klausen P., et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 99:2002;1314-1319.
10. Jolliffe L.K. Humanized antibodies enhancing therapeutic utility through antibody engineering. Int Rev Immunol. 10:1993;241-250.
11. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program. J Clin Oncol. 16:1998;2825-2833.
12. McLaughlin P., Hagemeister F.B., Grillo-Lopez A.J. Rituximab in indolent lymphoma the single-agent pivotal trial. Semin Oncol. 26:(suppl 14):1999;79-87.
13. Gullick W.J., Downward J., Parker P.J., et al. The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies. Proc R Soc Lond B Biol Sci. 226:1985;127-134.
14. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
15. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
16. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization poor prognosis in node-negative breast carcinomas. J Clin Oncol. 15:1997;2894-2904.
17. Pegram M.D., Pauletti G., Slamon D.J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 52:1998;65-77.
18. Izumi Y., Xu L., di Tomaso E., et al. Tumour biology herceptin acts as an anti-angiogenic cocktail. Nature. 416:2002;279-280.
19. Pietras R.J., Fendly B.M., Chazin V.R., et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829-1838.
20. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:1999;2241-2251.
21. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 20:2002;1215-1221.
22. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer. 37:(suppl 1):2001;18-24.
23. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol. 12:(suppl 1):2001;49-51.
24. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.
25. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:2002;719-726.
26. de Klein A., van Kessel A.G., Grosveld G., et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 300:1982;765-767.
27. Strife A., Lambek C., Wisniewski D., et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res. 48:1988;1035-1041.
28. Buckle A.M., Mottram R., Pierce A., et al. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells. Mol Med. 6:2000;892-902.
29. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
30. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
31. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
32. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 20:2002;1692-1703.